The global nutraceutical ingredients market is projected to grow from USD 108.33 billion in 2026 to USD 161.53 billion by 2031, a CAGR of 7.3%, with Asia-Pacific expanding at 11.3%—the fastest regional rate. But the more consequential shift is qualitative. At FIC 2026, the industry’s focus moved decisively from “whether an ingredient works” to “why it works and how precisely it can act” , with joint health, gut-brain axis, and postbiotics moving into clinical-evidence territory.
For nutritional raw material suppliers, this means functional proteins—already 44.34% of the market in 2025—must be paired with mechanism-level documentation, not just commodity pricing. Delivery technologies such as microencapsulation and liposomal systems are becoming differentiators for stability and bioavailability, while regulatory and health-claim requirements remain the primary restraint on formulation velocity. The winning raw material portfolio in 2026 is not the broadest—it is the one that can bridge nutritional functionality with processing performance, stability, and claim substantiation.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy